Results 111 to 120 of about 1,327 (120)

People also looked at

Frontiers in Oncology, 2021
Cheng Chen, Xiao-Yuan Chu, Yulu Zhao
exaly  

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements

Cancers, 2022
Silvia Novello, Maria Lucia Reale, Marco De Filippis   +2 more
exaly  

The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis

Clinical Oncology, 2017
Frankie Mo, Victor Ho Fun Lee, V H F Lee
exaly  

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib

Cancer Treatment and Research Communications, 2019
Nathan A Pennell, Hossein Borghaei, Chad V Pecot   +2 more
exaly  

The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma

Cancers, 2019
Federica de Luca, Fabio Mele, Sabino Strippoli   +2 more
exaly  

Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression

Clinical Lung Cancer
Cole Friedes, William P Levin
exaly  

The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?

Clinical Oncology, 2019
D Palma, A C Tree
exaly  

Radiotherapy combined with locoregional hyperthermia for oligoprogression in metastatic melanoma local control

Therapeutic Advances in Medical Oncology
Piotr Rutkowski, Aneta Borkowska, Paulina Chmiel   +2 more
exaly  

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)

JTO Clinical and Research Reports
Hajime Asahina, Toshiyuki Harada, Osamu Honjo   +2 more
exaly  

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

Lancet, The
Afsheen Iqbal, Rachel Sanford, Jeeban P Das   +2 more
exaly